Pharmacovigilance is a crucial business component for any pharmaceutical company - just like the manufacturing of a F1 car or a fighter jet, safety is an imperative consideration for the manufacturers. Good benefit-risk management and communication is crucial to business success. A core part of good benefit-risk management is ensuring that there is optimal awareness through collection, collation, assessment, and appropriate response to all available safety information.
This 10 module online course is intended to enable its students to understand key regulations and guidelines relating to PV and how to achieve compliance with these standards.
This 10 module course will provide you with information about the key aspects of Pharmacovigilance:
Arthur P. Meiners studied medicine in Rotterdam and then trained and worked as an internist-nefrologist. He joined the Dutch Agency for the Medicines Evaluation Board in 1991 where he set up and headed the pharmacovigilance department. In 2001 he became QPPV for J&J, advisory board member to the Pharmacovigilance Platform Netherlands, joined the (PhRMA) EU Pharmacovigilance working group, and from 2002 to 2008 was a board member of Janssen Cilag International.
Since early 2010 he is available as a pharmacovigilance consultant for PV projects, including issue management, system review & improvement and training.